Sema4 Signal® | Data-Driven Precision Oncology Solutions


Sema4 Signal enables and advances precision oncology care, from prevention to treatment to remission


Identify, treat, and monitor cancer with our family of data-driven precision oncology solutions


Make better care decisions guided by our complex analytics, digital tools, and exome-based testing


Partner with us to deliver bespoke care solutions as unique as your patient’s cancer



Integrated solutions



Detection of hereditary cancer variants, delivered via the Sema4 Traversa™ genomic platform to inform better care decisions for individuals with and without cancer. Learn more.

Tumor Profiling

Comprehensive molecular profiling insights to help providers identify therapies and clinical trials for their patients today, and take advantage of the therapies and trials of tomorrow. Learn more.


Advanced natural language processing (NLP) tools, powered by our Centrellis® health intelligence platform to structure clinical data and compare patient cohorts, enabling treatment decisions, population-level insight, and trial matching. Learn more.

Learn how Sema4 is leading in the mission to address healthcare disparities and advance health equity in precision cancer care through our REPRESENT Study.

The Impetus for Joining the Mission of Sema4

Sema4 Chief Medical Science Officer Dr. William K. Oh discusses how data can drive precision oncology and make an impact in cancer care for healthcare providers and their patients.


Why partner with us?



An extension of your precision oncology team

Sema4 originated in a large healthcare system, so we understand the testing capabilities, service models, and analytical insight required to advance the standard of cancer care. We partner with health systems, practices, individuals, and payors to enable the oncology care of today while driving the therapeutic advances of tomorrow. Whether your team is looking for an end-to-end solution or a standalone service, we work with you to tailor an offering that delivers the best precision oncology care. View our provider brochure for more information.


State-of-the-art molecular technologies

As one of the leading genomics laboratories in the world, we employ the latest next generation sequencing (NGS) technologies to detect germline and somatic variants in our CAP-accredited (The College of American Pathologists) and CLIA-certified (Clinical Laboratory Improvement Amendments) facility in Branford, CT. We have run over half a million large NGS panels and recently expanded our COVID-19 testing capacity to 15,000 tests per day. Our second, 70,000 sq. ft., CT lab opened in Stamford, expanding our genetic testing capabilities. Learn more about our somatic and germline testing technologies.


Best-in-class service and support

At Sema4, we understand the complexities of cancer care and have extensive experience in delivering exceptional service support. Our billing experts, board-certified genetic counselors, clinical team, educational resources, and digital tools guide patients during stressful times. For providers, our Client Services team is here to ensure that you receive the type of high-touch support that fits your specific needs. Learn more about our somatic and germline support.



At the forefront of cancer research

Directed by world leaders in predictive modeling, artificial intelligence, and genomics, Sema4’s research focuses on structuring data into validated clinical insights. Our researchers have published more than 1,000 peer-reviewed papers in the last five years on subjects including prognostic biomarkerstumor profiling, and chemoimmunotherapy, and indications including non-small cell lung cancerglioblastoma, and multiple myeloma. We collaborate with major health systems, research consortia, and advocacy groups and have recognized expertise in customized clinical trial development and recruitment, making us a trusted partner to pharmaLearn more about our research.

Participating with:




Sema4 Signal offers a unique holistic approach



Products from the Sema4 Signal portfolio can be leveraged individually or as part of a holistic solution. Integration of our germline, somatic, and informatics tools, along with customized services to meet your needs, can help drive better personalized care.


Broad range of exome-based sequencing services to identify individuals with increased hereditary cancer risk and detect somatic and germline alterations in those with cancer


Data-driven insights leveraging real-world evidence to guide treatment decisions, including clinical trial matching, and inform on patient populations


Continuous monitoring of patient health and emerging actionable clinical advances and trials

Connect with us today

Kindly fill out the form below and we’ll schedule a time to discuss your needs. Or feel free to call us at 833-486-6260.